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Sphingomyelin-cholesterol liposomes significantly enhance the
pharmacokinetic and therapeutic properties of vincristine in murine and
human tumour models
MS Webb*, TO Harasym, D Masin, MB Bally and LD Mayer
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Summary This study reports on the development of a liposomal formulation of vincristine with significantly
enhanced stability and biological properties. The in vitro and in vivo pharmacokinetic, tumour delivery and
efficacy properties of liposomal vincristine formulations based on sphingomyelin (SM) and cholesterol were
compared with liposomes composed of distearoylphosphatidylcholine (DSPC) and cholesterol. SM/cholesterol
liposomes had significantly greater in vitro stability than did similar DSPC/cholesterol liposomes. SM/
cholesterol liposomes also had significantly improved biological properties compared with DSPC/cholesterol.
Specifically, SM/cholesterol liposomes administered intravenously retained 25% of the entrapped vincristine
after 72 h in the circulation, compared with 5% retention in DSPC/cholesterol liposomes. The improved
retention properties of SM/cholesterol liposomes resulted in plasma vincristine levels 7-fold higher than in
DSPC/cholesterol liposomes. The improved circulation lifetime of vincristine in SM/cholesterol liposomes
correlated with increased vincristine accumulation in peritoneal ascitic murine P388 tumours and in sub-
cutaneous solid A431 human xenograft tumours. Increased vincristine delivery to tumours was also accom-
panied by increased anti-tumour efficacy. Treatment with SM/cholesterol liposomal formulations of vincristine
resulted in greater than 50% cures in mice bearing ascitic P388 tumours, an activity that could not be achieved
with the DSPC/cholesterol formulation. Similarly, treatment of mice with severe combined immunodeficiency
(SCID) bearing solid human A431 xenograft tumours with SM/cholesterol vincristine formulations delayed the
time required for 100% increase in tumour mass to >40 days, compared with 5 days, 7 days and 14 days for
mice receiving no treatment or treatment with free vincristine or DSPC/cholesterol formulations of vincristine
respectively.
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Vincristine is a cancer chemotherapy agent that possesses
therapeutic activity against a wide range of human malignan-
cies. Since vincristine is a cell cycle-specific agent, its anti-
tumour potency is very sensitive to the duration of its
exposure to the tumour cells (Horton et al., 1988). In view of
this relationship, it is not unexpected that liposomal carriers
have been employed to improve the efficacy of vincristine
since the effectiveness of liposomes in extending the circula-
tion lifetime of a wide variety of drugs is well established.
Previous studies have demonstrated that the anti-tumour
efficacy of liposomal vincristine increases with increasing
liposome circulation lifetime and with increased retention of
the encapsulated drug in the liposomes after i.v. administra-
tion (Mayer et al., 1990a, 1993; Boman et al., 1994). Our
efforts have, therefore, focused on the development of
liposomal formulations of vincristine having enhanced phar-
macokinetic properties and drug retention characteristics.
This can be achieved by alterations in lipid and int-
raliposomal buffer composition.
Previous work with liposomal vincristine has been based
on vesicles containing phosphatidylcholine (PC), usually egg
PC or distearoyl-PC (DSPC), and cholesterol (Mayer et al.,
1993). Typically, vincristine loading into liposomes is effected
using a transmembrane pH gradient encapsulation procedure
employing an intraliposomal pH of 4.0 (Mayer et al., 1990b).
However, encapsulated vincristine leaks from liposomes foll-
owing i.v. administration, 85-90% of the entrapped drug
being released from DSPC/cholesterol liposomes within the
plasma compartment within 24 h (Boman et al., 1994). Vin-
cristine retention within liposomes both in vitro and in vivo is
significantly improved in liposomes possessing a larger trans-
membrane pH gradient (i.e. intraliposomal 0.3 M citrate buff-
er at pH 2.0), and these liposomal formulations have imp-
roved efficacy against P388 tumours (Boman et al., 1994).
Further, a synergistic improvement of in vivo drug retention
and anti-tumour efficacy was obtained in liposomes with the
larger transmembrane pH gradient (intraliposomal pH 2.0)
and containing 10 mol% of the ganglioside GM, (Boman et
al., 1994).
While the liposomal vincristine formulation employing an
intraliposomal pH of 2.0 and 10 mol% GM, is therap-
eutically very efficacious, it is unlikely to be of utility in a
clinical setting. Not only is GM1 potentially an antigenic lipid
that may limit repeated administration of this formulation,
but at pH 2.0 the acid-catalysed hydrolysis of the PC compo-
nent of the liposomes will occur at a significant rate and is
likely to limit the ability of the liposomes to maintain their
membrane permeability characteristics. This paper reports
experiments examining the biological properties of liposomal
formulations composed of sphingomyelin (SM) and chol-
esterol compared with those of DSPC and cholesterol. This
approach was based on the expectation that liposome
stability both in vitro and in vivo could be enhanced by the
development of liposomes lacking ester-linked acyl chains. As
the aliphatic chain of sphingomyelin is amide linked, we
expected sphingomyelin to be significantly less susceptible to
hydrolysis or enzymatic degradation than the ester-linked
fatty acids that are typical constituents of phosphatidyl-
cholines. Furthermore, because the headgroup moiety of
sphingomyelin is identical to that of phosphatidylcholines, it
was expected that liposomes composed of sphingomyelin and
cholesterol would have pharmacokinetic and tumour delivery
characteristics similar to those of DSPC/cholesterol lipo-
somes.
Materials and methods
Materials
Distearoylphosphatidylcholine (DSPC) and egg sphingomy-
elin (SM) were purchased from Avanti Polar Lipids and used
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Sigma (St Louis, MO, USA) and polyethylene glycol2m-
distearoylphosphatidylethanolamine (PEG2wo-PE) was ob-
tained from Northern Lipids (Vancouver, British Columbia,
Canada). Vincristine sulphate was obtained from Eli Lilly,
Canada (Oncovin). Cholesteryl-4-hexadecyl ether (CHDE)
radiolabelled with 3H or 14C (custom synthesis) was obtained
from New England Nuclear, while [3H]vincristine was
obtained from Amersham, Canada. Fetal bovine serum was
purchased from ICN Biomedicals (Costa Mesa, CA, USA).
BioGel A-lSm was obtained from BioRad Laboratories. All
other chemicals were obtained from Sigma. Female BDF1
and CD-l mice (8-10 weeks old) were obtained from Charles
River. Female SCID mice (8-10 weeks old) were bred at the
British Columbia Cancer Agency Animal Breeding Facility.
P388 cells were obtained from the NCI tumour repository
and were maintained by weekly passage in BDF1 mice. A431
cells were obtained from ATCC and maintained in culture.
Liposome preparation
Lipids were dissolved in chloroform or chloroform contain-
ing trace amounts of methanol, then mixed at the indicated
molar ratios. The lipid mixtures used in this study were
DSPC/Chol (55:45 mol/mol), SM/Chol (55:45 mol/mol) and
SM/Chol/PEG20W-PE (55:40:5 mol/mol/mol). Excess solvent
was removed under a stream ofnitrogen gas then the residual
solvent was removed from the lipid film under high vacuum
for 3-16 h. Lipids were dispersed by the addition of 0.3 M
citrate buffer (pH 4.0 or 2.0) to achieve a final lipid concen-
tration of either 50 or 100 mgml-'. Hydration of the lipid
was facilitated by vortexing and heating at 65C. Equili-
bration of the solute between the inside and outside of the
liposomes was achieved by five freeze-thaw cycles between
- 196°C and 60°C (Mayer et al., 1985). Large unilamellar
vesicles were produced by repeated extrusion of the multi-
lamellar liposomes through stacked 0.1 ILm filters (Poretics,
Livermore, CA, USA) held at 60-65°C in a thermobarrel
extruder (Lipex Biomembranes, Vancouver, Canada). Lipo-
some size distributions were confirmed by quasielastic light
scattering using a Nicomp model 270 submicron particle
sizer; these preparations typically had mean diameters of
120-130 nm.
Measurement oflipid hydrolysis
Large unilamellar liposomes of DSPC/Chol or SM/Chol were
prepared as described above in 0.3 M citrate buffer at pH 2.0
and then diluted to 3.2 mg lipid ml-'. The liposomes were
incubated at 37°C for various times, then frozen at - 80°C
until the determination of lipid hydrolysis. Lipid dispersions
were thawed, then extracted into chloroform-methanol and
concentrated under a stream of nitrogen gas. Known quan-
tities of lipid were spotted onto K6F thin-layer chroma-
tography plates and developed in chloroform-methanol
water-ammonium hydroxide (65:25:4:0.3, by volume). Lipids
were visualised in iodine vapour and then the appropriate
regions of the plate were recovered by scraping and analysed
for phosphorus (Bartlett, 1959). Total hydrolysis of DSPC
was determined from the amount of MSPC present in the
samples and corrected to total hydrolysis (MJ Hope, per-
sonal communication); hydrolysis of sphingomyelin was cal-
culated from the difference between the amount of lipid
chromatographed and that recovered as non-hydrolysed
sphingomyelin. Calibration curves were determined for each
of DSPC, MSPC and sphingomyelin.
Vincristine entrapment in liposomes
Uptake of vincristine into large unilamellar liposomes was
achieved using a pH gradient-dependent procedure described
previously (Mayer et al., 1993). Briefly, a solution of vinc-
ristine sulphate was added to liposomes at a drug-lipid ratio
of 0.1:1 (w/w) and equilibrated at 60°C for 5-O min. Vinc-
ristine uptake in response to a transmembrane pH gradient
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was initiated by the addition of 0.5 M disodium hydrogen
phosphate to bring the external pH to 7.2-7.6. Uptake was
allowed to proceed for 10min at 60°C and typically had a
trapping efficiency greater than 95% (Mayer et al., 1993).
Liposome pharmacokinetics and tumour loading
Liposomes of DSPC/Chol, SM/Chol or SM/Chol/PEG20W-PE
containing the non-exchangeable and non-metabolised
radiolabel ['4C]CHDE were prepared as described above.
Empty liposomes or liposomes loaded with [3H]vincristine as
described above were diluted to the appropriate concentra-
tion with 150 mM sodium chloride, 20 mM Hepes [pH 7.5;
Hepes-buffered saline (HBS)], then injected i.v. into BDFl
mice at a vincristine dose of 2 mg kg-' (lipid dose of
20 mg kg-'). For tumour loading experiments with the
murine P388 ascitic tumour, BDF1 mice were injected i.p.
with 106 P388 cells 24 h before liposome injection. At various
times after liposome injection, blood was obtained by heart
puncture and the peritoneal cavity was lavaged with 4 ml of
HBS. For solid tumour experiments, SCID mice were
bilaterally injected s.c. in the shoulders or flanks with 2 x 106
A431 cells about 14 days before treatment. SCID mice bear-
ing A431 tumours of approximately 100-200 mg weight were
randomised, then treated with free vincristine or with vincris-
tine loaded in either DSPC/Chol or SM/Chol liposomes as
described above. All mice received a single i.v. injection
corresponding to a vincristine dose of 2.0 mgkg-'. At
various times after treatment, blood was obtained by heart
puncture and the tumours recovered. In all cases, lipid and
vincristine were quantified by liquid scintillation counting
(LSC) of plasma, peritoneal lavage and 10% homogenates of
the solid tumours.
Protein binding by liposomes
For serum protein binding assays, 10 mg of either DSPC/
Chol or SM/Chol liposomes labelled with ['4C]CHDE was
brought to an external pH of 7.2-7.6, then diluted to
20 mgml1' with HBS. Liposomes were then incubated with
500 il of fetal bovine serum (prefiltered through a 0.22tim
filter) for 30 min at 37°C. Serum protein not bound to the
liposomes was removed by passing the sample over a 1 cm
(i.d.) x 18 cm BioGel A-5m column (in HBS) at 35 ml h-'.
Fractions (1 ml) were assayed for protein (Sigma bicin-
choninic acid protein assay kit) and lipid (LSC) and the
adsorbed protein was calculated after correction for co-
eluting serum protein.
Efficacy ofliposomal vincristine against ascitic P388 andsolid
A431 tumours
Large unilamellar liposomes of DSPC/Chol, SM/Chol and
SM/Chol/PEG20,-PE were prepared as described above and
loaded with vincristine at a vincristine-lipid ratio of 0.1:1
(w/w). For efficacy experiments with the murine ascitic P388
tumour, free and liposomal vincristine was injected i.v. into
BDF1 mice that had been inoculated 24 h earlier with an i.p.
injection of 106 P388 cells. Concentrations were adjusted to
achieve vincristine doses of 2.0, 3.0 and 4.0mgkg-'. Animal
weights and survival were followed during the subsequent 60
days. Animals surviving for 60 days were reinjected with 106
P388 cells to evaluate the immune component of long-term
survival. Survival times (in days) for each treatment were
ranked and statistically analysed using Cox's F-test. Comp-
arisons indicated as having statistical significance had P-
values from the Cox's F-test that were<0.05.
For efficacy experiments with the solid human A431
tumour (a squamous cell carcinoma), SCID mice inoculated
bilaterally 14 days earlier with 2 x 106 A431 cells received a
single i.v. injection of free vincristine or of vincristine loaded
into either DSPC/Chol or SM/Chol liposomes. Concentrat-
ions were adjusted to achieve vincristine doses of 2.0
mgkg-'. Animal weights and tumour sizes were followed
during the subsequent 40 days. Tumour weight was deter-Liposomal vincristine
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mined by measuring tumour dimensions and calculating
weight with the equation (Tomayko and Reynolds, 1989):
(n x 6') x length x width x depth
Results
In vitro comparison ofDSPC/Chol andSMIChol liposomes
The chemical stability of liposomes composed of SM/Chol
and DSPC/Chol was compared based on observations that
hydrolysis of DSPC to MSPC and free fatty acid leads to
increased vincristine leakage rates from the liposome (L
Mayer, unpublished data) and on the expectation that lower
hydrolysis rates should occur in SM-based lipid carriers.
Liposomes of DSPC/Chol (55:45 mol/mol) or SM/Chol
(55:45 mol/mol) were prepared in 0.3 M citrate buffer at pH
2.0 and incubated at 37°C in order to accelerate lipid hydro-
lysis and facilitate the comparison of acid-induced hydrolysis
rates in these liposomes. Under these conditions, liposomes
composed of SM/Chol were approximately 100-fold less
susceptible to acid hydrolysis than were DSPC/Chol lipo-
somes (Table I). Specifically, the rates of hydrolysis at 37°C
and pH 2.0 were 0.090% per hour and 9.11% per hour in
SM/Chol and DSPC/Chol liposomes respectively. It should
be noted that, although extreme conditions (pH 2.0, 37C)
were used to accelerate the hydrolysis rates in SM/Chol and
DSPC/Chol liposomes, similar results have been observed
during incubation of liposomes at pH 4.0 and at various
temperatures between 4°C and 37°C (data not shown).
The interactions of DSPC/Chol and SM/Chol liposomes
with blood components were also compared in order to
identify possible differences that might affect the biological
behaviour of liposomal vincristine. The leakage of vincristine
from liposomes during 6 h of incubation in plasma at 37°C
(50 sg drugml-' plasma) was 1.42-fold faster from DSPC/
Chol liposomes than from SM/Chol liposomes (linear
leakage rates of 2.7% per hour and 1.9% per hour for
DSPC/Chol and SM/Chol respectively; Table I). These
results correlated with observations where DSPC/Chol lipo-
somes adsorbed 13.7 Lg protein mg-' lipid from plasma,
while no adsorbed protein could be detected on SM/Chol
liposomes (detection limit of 1.75 lg protein mg' lipid;
Table I). Taken together, the above data suggest that SM/
Chol liposomes might exhibit properties well suited for
extending the circulation lifetime of encapsulated vincristine
and potentially leading to a significant improvement in its
therapeutic activity.
Lipid and drugpharmacokinetics in BDFJ mice
We have examined the lipid and drug pharmacokinetics of
DSPC/Chol and SM/Chol liposomal formulations of vincris-
tine. These studies involved the determination of plasma
clearance rates of both empty and vincristine-loaded lipo-
somes. Plasma levels of empty DSPC/Chol and SM/Chol
liposomes are shown in Figure 1. Liposomes composed of
SM/Chol were removed from the circulation at a rate slower
than were DSPC/Chol liposomes. Specifically, the half-lives
of lipid removal from the circulation, as calculated from the
slopes of the ln% lipid remaining vs time, were 4.0 h for
DSPC/Chol liposomes and 5.7 h for SM/Chol liposomes
(r2 > 0.996). In liposomes loaded with vincristine, the clear-
ance rates for both liposome types were slower, presumably
because of the effect of the drug on the phagocytic activity of
the RES (Mayer et al., 1995). However, there was no statis-
tical difference between clearance rates of DSPC/Chol and
SM/Chol liposomes in formulations containing vincristine
(Figure 2). Specifically, the half-lives for removal of vincr-
istine-loaded liposomes from the circulation were 15.7 h for
DSPC/Chol liposomes compared with 18.9 h for SM/Chol
liposomes (Table II). The removal of liposomes from the
circulation could be accurately described by a first-order
exponential process, as indicated by the linear relationship
shown in the semi-log plot of Figure 2 (r2 > 0.980).
The vincristine retention characteristics of the liposomes
were significantly altered by changes in the lipid composition
of the vesicles. Vincristine leakage from DSPC/Chol lipo-
somes resulted in 5.6% of the originally encapsulated vincris-
tine remaining entrapped after 72 h in circulation (Figure 3).
In contrast, vincristine leakage from SM/Chol liposomes was
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Figure 1 Amount of lipid remaining in the circulation of BDFI
mice injected with liposomes composed of DSPC/Chol (0) or
SM/Chol (0). The injected dose of lipid was 20 mg kg-', corres-
ponding to a total injection of approximately 430 Lg of lipid.
Data represent means (± s.e.) of three mice; where standard
error bars are not visible, they are smaller than the size of the
symbol.
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Figure 2 Amount of lipid remaining in circulation in BDFI mice
injected with large unilamellar liposomes of DSPC/Chol (0) or
SM/Chol (0). Injected liposomes were loaded with vincristine at
a drug-lipid ratio of approximately 0.1:1 (w/w). The injected
dose of lipid was 20 mg kg-', corresponding to a total injection
of approximately 430#Lg of lipid. Data represent means ( ± s.e.)
of three mice; where standard error bars are not visible, they are
smaller than the size of the symbol.
Table I Summary of the in vitro properties of DSPC/Chol and SM/Chol liposomes
Hydrolysis rate" Vincristine leakageb Protein adsorption
Liposome (% h-') (% h-') (j&gproteinmg-' lipid)
DSPC/Chol 9.11 (0.999) 2.7 (0.982) 13.7
SM/Chol 0.090 (0.520) 1.9 (0.997) < 1.75
aHydrolysis at pH 2.0, 37C (rm of the linear regression). bLeakage of vincristine
incubated in plasma during 6 h at 37C (rm of the linear regression).
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Table II Plasma clearance properties of free and liposomal vincristine in BDFI mice bearing P388
tumours
tI/2(r2)a 24 hb 72 hb
Formulation L V VIL L V VIL L V V/L
Free vincristine - 0.16 - - 0.156 - - - -
(0.57) (0.035)
DSPC/Chol 15.7 8.0 17.1 160 4.86 30.3 22.4 0.10 5.6
(0.98) (0.99) (0.99) (10) (0.40) (0.52) (4.3) (0.03) (2.9)
SM/Chol 18.9 12.1 33.3 186 12.5 67.4 26.1 0.66 25.0
(0.98) (0.99) (0.99) (8.7) (0.52) (0.33) (7.6) (0.21) (1.1)
SM/Chol/PEG2000-PE 24.0 12.7 26.8 243 12.1 49.7 62.8 0.89 13.8
(0.99) (0.99) (0.99) (11) (0.87) (1.3) (16.5) (0.31) (1.1)
aThe half-lives(t012), in hours, forthe removal oflipid (L) and vincristine (V) fromcirculation and for the
decrease in the vincristine-lipid ratio (V/L) were calculated from the linear regressions ofthe In (jsg ml-'
plasma) vs time or from the In (% vincristine/lipid remaining) vs time plots. The r2 values for these
regressions are given in brackets. bThe levels oflipid (L) and ofvincristine (V) (jg ml-' plasma) at 24 and
72 h after injection ( ± standard error). The vincristine-lipid ratio (V/L), expressed as a percentage ofthe
ratio at injection, at 24 and 72 h after injection (± s.e.).
much slower, with 25.0% of the entrapped drug remaining in
the liposomes 72 h after injection (Figure 3). The half-lives of
vincristine leakage from the liposomes were 17.1 h for DSPC/
Chol and 33.3 h for SM/Chol liposomes (Table II). As des-
cribed for the removal of liposomes from circulation, vincris-
tine leakage from both liposome types could be accurately
described as a first-order exponential decay process. Addi-
tional increases in the retention of vincristine in SM/Chol
liposomes were not observed in the presence of a larger
transmembrane pH gradient (pH, = 2.0, data not shown).
This is in contrast to previous studies using DSPC/Chol in
which a 2-fold increase in drug retention was observed when
the internal buffer was changed from pH 4 to pH 2 (Boman
et al., 1994).
The anti-tumour efficacy of liposomal vincristine is assoc-
iated with the amount of the drug remaining in circulation
(Mayer et al., 1993; Boman et al., 1994) and, therefore, is
dependent on both liposome longevity in the circulation and
vincristine retention within the liposome. Free vincristine was
rapidly removed from the circulation; the amount of vincris-
tine in circulation at 4 and 24 h after injection was 30- to
80-fold lower than for liposomal vincristine (Figure 4). The
total amount of vincristine remaining in the circulation was
significantly lower for the liposomal DSPC/Chol formula-
tions than for the SM/Chol formulation (Figure 4). At 72 h
after i.v. injection, the amount of vincristine remaining in
circulation was 0.10 ig vincristineml-' plasma for DSPC/
Chol compared with 0.67 tg vincristine ml-' plasma for SM/
Chol liposomes (Figure 4). The half-life for plasma vincris-
tine levels was 8.0 h for DSPC/Chol liposomes compared
with 12.1 h for SM/Chol liposomes (Table II). The lower
levels ofplasma vincristine in the DSPC/Chol liposomes were
primarily a consequence of the more rapid leakage ofvincris-
tine from DSPC/Chol liposomes (Figure 3).
These pharmacokinetic studies of liposomal vincristine
were extended to a formulation composed of SM/Chol/
PEG20,,-PE. PEG20o-PE is a lipid known to confer increased
circulation longevity on liposomes (Allen and Hansen, 1991;
Allen et al., 1991). A significant increase in the amount of
lipid remaining in circulation was achieved by the addition of
5 mol% PEG20w-PE to the SM/Chol mixtures. At 72 h after
i.v. injection, 62.8tLg lipidml-' plasma remained in circula-
tion for SM/Chol/PEG2WO-PE liposomes compared with
26.1 ygml1' plasma for SM/Chol liposomes and
22.4pigml-' plasma for DSPC/Chol liposomes (Table II).
This was reflected by a significant increase in the half-life for
lipid clearance from the circulation to 24.0 h for SM/Chol/
PEG20W-PE liposomes. However, the presence of 5 mol%
PEG20W-PE in SM/Chol liposomes also caused a significant
increase in vincristine permeability. Specifically, only 13.8%
of the entrapped vincristine remained in the liposomes after
72 h in the circulation, representing a half-life for vincristine
leakage of 26.8 h for SM/Chol/PEG20w-PE liposomes (Table
II). As a consequence of the higher vincristine-lipid ratio in
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Figure 3 Vincristine-lipid ratio, expressed as a percentage of the
injected ratio, in the plasma of BDF1 mice at various times after
the injection of large unilamellar liposomes ofDSPC/Chol (0) or
SM/Chol (@). Mice were injected with liposomes at a vincris-
tine-lipid ratio of approximately 0.1:1, corresponding to a lipid
dose of 20 mg kg-' and a vincristine dose of 2.0 mg kg-'. Total
amounts injected were approximately 430gg of lipid and 43 sg of
vincristine. Data represent means (± s.e.) of three mice; where
standard error bars are not visible, they are smaller than the size
of the symbol.
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Figure 4 Total vincristine remaining in the plasma of BDF1
mice at various times after i.v. administration of free vincristine
(0) or of large unilamellar liposomes of DSPC/Chol (0) or
SM/Chol (0) at a vincristine-lipid ratio of 0.1:1 (w/w), corres-
ponding to a lipid dose of 20 mg kg-' and a vincristine dose of
2.0 mg kg-'. Total amounts injected were approximately 430tLg
of lipid and 43ILg of vincristine. Data represent means (± stand-
ard error) of three mice; where standard error bars are not
visible, they are smaller than the size of the symbol.Liposomal vincristine
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SM/Chol liposomes, compared with SM/Chol/PEG20M-PE
liposomes, and the more rapid removal of SM/Chol
liposomes from circulation than for SM/Chol/PEG20o-PE
liposomes, both formulations had equal amounts of vincris-
tine remaining in the circulation at all times between 4 h and
72 h after i.v. injection. Specifically, the half-lives for removal
of vincristine from the circulation were 12.7 h for SM/Chol/
PEG20W-PE, compared with 12.1 h for SM/Chol liposomes
(Table II). Therefore, we have observed no overall improve-
ment in vincristine circulation longevity in vivo by the addi-
tion of PEG20M-PE to SM/Chol liposomes.
Vincristine accumulation in the site ofP388 ascitic tumour
growth
In order to determine if the pharmacokinetic characteristics
observed for DSPC/Chol and SM/Chol in plasma affected
the tendency for vincristine and lipid to accumulate in an
extravascular site, we examined the accumulation of lipid and
drug in the peritoneal cavity of mice inoculated 24 h earlier
with P388 cells. No significant difference was observed in the
accumulation of lipid in the peritoneal cavity after administ-
ration of DSPC/Chol or SM/Chol liposomes (data not
shown). This result suggests that there was little or no diff-
erence between these liposome formulations in their abilities
to extravasate to the site of the peritoneal P388 tumour cell
inoculation. The amount of free vincristine accumulating in
the peritoneal cavity was highest (875 ng) at 7 min after
injection of the free drug and decreased to levels less than
217 ng within 4 h (Figure 5). The accumulation of vincristine
from DSPC/Chol liposomes in the peritoneal cavity peaked
at 628 ng vincristine per lavage at 4 h after liposome injection
and decreased to less than 188 ng vincristine per lavage at
times in the range between 24 and 72 h (Figure 5). In con-
trast, vincristine from SM/Chol formulations showed sus-
tained delivery of vincristine for up to 24-48 h after
liposome injection (Figure 5). Specifically, SM/Chol formula-
tions of vincristine delivered 889-605 ng of vincristine per
lavage over the time period between 4 and 24 h after injec-
tion. Vincristine accumulation in the peritoneal cavity from
SM/Chol did not decrease to levels equivalent to those from
DSPC/Chol liposomes until 48 h after injection. The total
exposure of P388 cells residing in the peritoneal cavity to
vincristine delivered by SM/Chol liposomes was approx-
imately 30% greater than that achieved by DSPC/Chol
liposomes. In addition, the accumulation of vincristine from
liposomes of SM/Chol/PEG20W-PE into the peritoneal cavity
of mice inoculated with P388 cells was identical to that
observed for SM/Chol liposomes (data not shown).
The vincristine-lipid ratios observed in both DSPC/Chol
and SM/Chol liposomes that had extravasated from the cir-
culation to the peritoneal cavity were similar to those
observed for liposomes remaining in the plasma. Specifically,
the vincristine-lipid ratios observed for SM/Chol liposomes
in the peritoneum were much greater than those for
peritoneal DSPC/Chol liposomes (Figure 6). In addition, the
peritoneal vincristine-lipid ratios were similar to those
observed in the plasma for both liposomal formulations
(Figure 6). These results suggest that the increased delivery of
vincristine to the peritoneal cavity by SM/Chol formulations
of vincristine, compared with DSPC/Chol formulations, was
not a consequence of delivery of free vincristine that had
leaked from liposomes in plasma. Rather, these data suggest
that both SM/Chol and DSPC/Chol liposomes, containing
vincristine, were extravasating from the circulation and
accumulating at the site where the P388 cells were residing,
as observed previously in similar systems (Mayer et al.,
1995).
Efficacy ofliposomal vincristineformulations against P388
tumours
Therapeutic studies were undertaken to determine if the in-
creased delivery of vincristine to the site of P388 tumour
growth observed for SM/Chol liposomes (Figure 5) resulted
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Figure 5 Accumulation of vincristine in the peritoneal cavity of
BDFI mice bearing peritoneal P388 tumour cells after i.v.
administration of free vincristine (0) or of large unilamellar
liposomes of DSPC/Chol (0) or SM/Chol (0) containing vinc-
ristine at a drug-lipid ratio of 0.1:1 and a vincristine dosage of
2.0 mg kg-'. Data represent means ( ± s.e.) of four mice; where
standard error bars are not visible, they are smaller than the size
of the symbol.
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Figure 6 Comparison of the vincristine-lipid ratio (expressed as
a percentage of the injected ratio) between liposomes remaining
in circulation (0, 0) and those extravasated to the peritoneal
cavity (P, 0) for DSPC/Chol (0, 0) and SM/Chol (0, *)
liposomes. Data for the vincristine-lipid ratios for liposomes in
plasma were taken from Figure 3 for comparison.
in an increase in anti-tumour activity. BDF1 mice bearing
P388 tumours were untreated or were treated with free vinc-
ristine or liposomal vincristine formulations of DSPC/Chol
or SM/Chol at a drug-lipid ratio of 0.1:1.0 (w/w). For free
vincristine at 2.0, 3.0 and 4.0 mg kg-', a significant increase
in survival was observed compared with controls.
Specifically, median survival increased from 11.0 days to
16-16.5 days, representing increase in lifespan (ILS) values
of 33-38% (Table III and Figure 7).
At a vincristine dose of 2 mg kg-', the DSPC/Chol for-
mulation increased the median survival to 26.5 days
(ILS = 141% compared with control mice receiving no treat-
ment), however, the SM/Chol formulation was significantly
more effective (P<0.05) than DSPC/Chol, with 50% of the
SM/Chol treatment group surviving at 60 days after adminis-
tration of the P388 tumours (median survival>48.5 days,
ILS>341%; Figure 7 and Table III). The greatest anti-
tumour efficacy of the liposomal formulations of vincristine
was observed at the 3 mg kg-' vincristine dose, at which
SM/Chol-entrapped vincristine effected a 90% survival rate
(ILS>445% and median survival>60 days; Table III). The
SM/Chol formulation at 3 mg kg-' vincristine had a survival
curve that was significantly different (P<0.05) from the
DSPC/Chol formulation (Figure 7 and Table III). At a vinc-
ristine dose of 4mgkg-', both formulations had 40-50%
survival at 60 days after inoculation of the P388 tumour,
however at this vincristine dose the survival curves for the
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Table III Anti-tumour efficacy of free and liposomal formulations of vincristine in BDFI mice bearing P388
tumours
Drug dose" Maximum per cent weight Median survival Sixty-day
(mg kg-') Treatment change (day) (days) ILS* (%) survival
0 (control) - + 11.8 (7) 11.0 - 0115C
2.0 Free vincristine - 3.4 (5) 16.0 33 0/10
DSPC/Chol - 12.3 (4) 26.5 141 1/10"
SM/Chol - 10.9 (3) >48.5 >341 5/10"
3.0 Free vincristine - 9.0 (5) 16.5 38 0/10
DSPC/Chol - 14.6 (4) 34.5 214 3/lOe
SM/Chol - 14.9 (4) >60.0 >445 9/l1O
4.0 Free vincristine - 15.5 (5) 16.5 38 0/10
DSPC/Chol - 20.2 (5) 34.0 209 4/10
SM/Chol - 18.4 (4) >47.5 >332 5/10
'Lipid dose was 10-fold greater than the drug dose. bILS (increase in lifespan) was calculated from the median
survival times oftreatedandcontrolanimals. CAll treatmentgroupsweresignificantlydifferentfromthecontrolsat
P<0.05. "At 2.0mgkg-' vincristine, DSPC/Chol was significantly different from SM/Chol at P<0.05. eAt
3.0mg kg-' vincristine, DSPC/Chol was significantly different from SM/Chol at P<0.05.
different liposomal formulations were not significantly
different. Further, at 4mgkg'I vincristine, several deaths
occurred in the treated animals before the earliest of the
tumour-related deaths in control animals (days 6-9; Figure 7
and Table III). These deaths were consistent with vincristine
toxicity, rather than the results of excessive tumour growth
(Figure 7). There was no indication that SM/Chol formula-
tions were significantly more toxic than were the DSPC/Chol
formulations based on the nadir animal weights following
treatment (Table III). It should also be added that the anti-
tumour efficacy of SM/Chol/PEG20w-PE formulations con-
taining vincristine were not significantly different from those
observed for the SM/Chol formulations at all doses examined
(data not shown). Further, administration of empty
liposomes of SM/Chol at doses of either 40 or 80mgkg-'
lipid had no therapeutic benefit (data not shown).
Pharmacokinetics, tumour loading and therapy in SCID mice
bearing A431 tumours
Tumour loading and anti-tumour efficacy properties of
DSPC/Chol and SM/Chol liposomal formulations ofvincrist-
ine were -also determined in mice bearing solid human A431
squamous cell xenograft tumours. These experiments were
undertaken to ensure that the positive results observed in the
murine ascitic P388 tumour model were representative of
other tumour types. SCID mice bearing 100-200 mg solid
human A431 tumours were injected i.v. with free vincristine
or with liposomes of either DSPC/Chol or SM/Chol contain-
ing vincristine. Encapsulation of vincristine in DSPC/Chol
and SM/Chol liposomes increased the amount of vincristine
remaining in circulation 24 h after administration by 28- and
87-fold respectively compared with free vincristine (Figure
8a). As observed in BDF1 mice bearing P388 tumours, the
amount of vincristine remaining in the circulation in SM/
Chol liposomes at 24 h after injection was approximately
3-fold greater than for vincristine encapsulated in DSPC/
Chol liposomes (Figure 8a).
Improved vincristine circulation longevity correlated with
increases in the loading of vincristine in the A431 tumours
(Figure 8b). Specifically, free vincristine levels in A431
tumours were highest (0.856 gAg g-' tumour) at 0.5 h after
injection and decreased to 0.32fig g-' tumour at 24 h (Figure
8b). Encapsulation of vincristine in DSPC/Chol liposomes
increased the amount of vincristine present in A431 tumours
at 4-48 h after administration to 1.3-1.55 tg g-' tumour
respectively (Figure 8b). Encapsulation of vincristine in SM/
Chol liposomes resulted in a further increase in vincristine
delivery to A431 tumours at 24-48 h after injection to
2.8-3.2 tg g-' tumour, representing a 2-fold increase in the
delivery obtained with DSPC/Chol liposomes. As observed in
the murine ascitic tumour model, the vincristine-lipid ratios
observed in the solid human A431 tumours were very similar
to those observed in the plasma. That is, for vincristine
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Figure 7 Anti-tumour efficacy of free vincristine and liposomal
formulations of vincristine. BDFI mice bearing P388 tumours
were untreated (O) or were injected with free vincristine (0) or
large unilamellar liposomes of DSPC/Chol (0) or SM/Chol (0)
containing vincristine at a drug-lipid ratio of 0.1:1 (w/w).
Concentrations were adjusted before injection to achieve vincr-
istine doses of 2.0 (a), 3.0 (b) and 4.0 (c) mg kg-'.
encapsulated in DSPC/Chol liposomes, the vincristine-lipid
(w/w) ratios at 24 h after injection were 0.022 in the plasma
and 0.029 in the tumour, while for vincristine encapsulated in
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Figure 8 Plasma (a) and tumour (b) levels of vincristine after
administration of free and liposomal vincristine in SCID mice
bearing A431 tumours. SCID mice bearing two A431 tumours
were injected i.v. with free vincristine (0) or with large unil-
amellar liposomes of DSPC/Chol (0) or SM/Chol (0) contain-
ing vincristine at a drug-lipid ratio of 0.1:1 (w/w). Vincristine
was injected at a dose of 2.0 mg kg-', representing a lipid dose of
20 mgkg-'. Data represent means (± s.e.) of three mice (six
tumours); where standard error bars are not visible, they are
smaller than the size of the symbol.
SM/Chol liposomes the vincristine-lipid ratios were 0.055 in
the plasma and 0.050 in the tumour.
The anti-tumour efficacy of free and liposomal vincristine
against A431 was closely correlated with vincristine accum-
ulation at the tumour site (Figure 9). SCID mice bearing the
A431 tumours that received no treatment showed a 100%
increase in tumour weight within 4-5 days after treatment
was initiated and required termination within 10 days when
the tumour exceeded 10% of the total body weight. Tumour-
bearing SCID mice treated with free vincristine at 2.0
mg kg-' had a brief delay in tumour growth (100% increase
in tumour weight achieved within 6-8 days) but required
termination between 10 and 12 days. In contrast, treatment
with vincristine encapsulated in DSPC/Chol liposomes
resulted in a significant delay in tumour growth (100% inc-
rease in tumour weight at 15-20 days, termination at 21
days after treatment). This therapy was further enhanced by
a single treatment of vincristine encapsulated in SM/Chol
liposomes. In this treatment group a small but consistent
decrease in tumour size was observed. At 15 days after
injection, several tumours were palpable but unmeasurable,
and by 33 days after treatment several tumours were not
palpable. Of the five mice (total of ten tumours) treated with
SM/Chol liposomal vincristine, one animal was killed early
because of tumour ulceration, not due to tumour growth. Of
the eight tumours remaining at 40 days after liposome injec-
tion, histological analysis indicated that all eight were
actively dividing squamous cell carcinomas of a mass
undetectable by physical examination. Therefore, treatment
with SM/Chol liposomal vincristine effected a significant
reduction in tumour growth, although none of the original
tumours were cured.
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Figure 9 Anti-tumour efficacy of free and liposomal vincristine
in SCID mice bearing A431 tumours. SCID mice bearing two
A431 tumours received no treatment (U) or were injected i.v.
with free vincristine (0) or with large unilamellar liposomes of
DSPC/Chol (0) or SM/Chol (0) containing vincristine at a
drug-lipid ratio of 0.1:1 (w/w). Vincristine was injected at a dose
of 2.0mgkg-1, representing a lipid dose of 20mgkg-'. Data
represent the weight of A431 tumours (expressed as a percentage
of the tumour weight immediately before treatment) and are the
means (± s.e.) of 8-10 tumours in 4-5 mice.
Discussion
Several reports have documented the ability of a variety of
liposomes to decrease the toxicity and/or improve the efficacy
of vincristine (Layton and Trouet, 1980; Mayer et al., 1990a,
1993, 1995; Vaage et al., 1993; Boman et al., 1994). Early
studies revealed that vincristine is relatively permeable to the
phospholipid membranes, a characteristic that limits the use
of lipids containing unsaturated fatty acids, such as egg PC
(Mayer et al., 1990a). Subsequent investigations (Mayer et
al., 1993, 1995; Boman et al., 1994) demonstrated that the
therapeutic activity of liposomal vincristine correlates with
the drug circulation lifetime and results from drug carried
directly to the tumour site within the lipid vehicle. Conse-
quently, liposomes that rapidly release entrapped vincristine
(i.e. egg PC liposomes) or are rapidly cleared by the reticulo
endothelial system after i.v. administration have only modest
pharmacological improvements over free vincristine (Mayer
et al., 1993). These observations initiated attempts to imp-
rove vincristine retention through the use of larger trans-
membrane pH gradients and/or the presence ofGM, (Boman
et al., 1994). While these alterations optimised the therapeutic
properties of liposomal vincristine, they also compromised
the clinical utility of the formulations owing to problems
associated with the use of GM, in human applications and
with the high rate of phospholipid hydrolysis and degrada-
tion of the liposomes in low-pH buffers. We therefore
examined the in vitro and in vivo properties of liposomal
formulations of vincristine that are based on sphingomyelin
rather than on phosphatidylcholine. This approach was
based on the possibility that the amide-linked aliphatic chain
of sphingomyelin would be more resistant to chemical and
biological degradation than would be the ester-linked acyl
chains of phosphatidylcholine (Table I).
Empty liposomes composed of SM/Chol displayed circula-
tion lifetimes that were increased compared with DSPC/Chol
liposomes (Figure 1). The extended circulation times for
empty SM/Chol liposomes is consistent with the lower
adsorption of serum proteins to SM/Chol liposomes. An
inverse relationship between protein opsonisation to lipo-
somes and circulation longevity has been reported previously
(Senior et al., 1985; Hwang, 1987; Chonn et al., 1992) and is
consistent with the importance of protein-liposome interac-
tion in liposome pharmacokinetics. Extended circulation
lifetimes for SM/Chol liposomes have also been observed by
other workers (Allen and Chonn, 1987; Allen et al., 1989).
However, it should be noted that previous reports employedan entrapped aqueous solute ("251-labelled tyraminylinulin) as
a marker for liposome distribution. Consequently, it is possi-
ble that the apparent increase in liposome longevity in the
presence of sphingomyelin (Allen and Chonn, 1987; Allen et
al., 1989) arose in part from increased solute retention by
sphingomyelin. In vincristine-loaded liposomes, we observed
no significant difference in circulation longevity between
DSPC/Chol and SM/Chol formulations (Figure 2). The app-
arent inconsistency between the relative circulation lifetimes
observed for empty and vincristine-loaded liposomes of
DSPC/Chol and SM/Chol may be related to the 'blockade'
effect of liposomes containing cytotoxic agents (Bally et al.,
1990; Parr et al., 1993). Vincristine released from DSPC/Chol
liposomes within macrophages may reduce the ability of
these cells to further remove liposomes from the circulation.
SM/Chol liposomes had significantly improved vincristine
retention characteristics compared with DSPC/Chol lipo-
somes (Figure 3). The effect of sphingomyelin on vincristine
retention resulted in a 6- to 7-fold increase in plasma levels
of vincristine between 48 and 72 h after i.v. administration in
BDF1 mice compared with the DSPC/Chol formulation of
vincristine (Figure 4). The increased levels of vincristine
remaining in circulation in the plasma using SM/Chol for-
mulations (Figures 4 and 8a) were correlated with greater
amounts of vincristine delivered to the site of P388 tumour
cell inoculation (the peritoneal cavity; Figure 5) and to sub-
cutaneous A431 tumours grown in SCID mice (Figure 8b) as
well as with increased efficacy against these tumours (Figures
7 and 9 and Table III). At vincristine doses of 2.0-3.0 mg
kg-1, SM/Chol formulations of vincristine were significantly
more effective than free vincristine or vincristine encapsulated
in DSPC/Chol formulations at reducing P388 and A431
tumour progression.
Recent studies on the relationship between vincristine
pharmacokinetics and therapeutic activity have demonstrated
that the increased drug accumulation in tumours and in-
creased anti-tumour activity observed for vincristine encap-
sulated in DSPC/Chol liposomes is a consequence of the
ability of the liposomes to deliver encapsulated vincristine
directly to the tumour site (Mayer et al., 1995). This is
consistent with previous studies which have shown that the
delivery of a liposomal drug to a tumour is associated with
extravasation of liposomes to the interstitial, or extra-
vascular, spaces of the tumours (Gabizon, 1992, 1994; Bally
et al., 1994; Yuan et al., 1994). Our analysis reported here is
consistent with these studies and suggests that the increased
delivery of vincristine to tumours by SM/Chol formulations
was the consequence of liposome extravasation into the
tumour and was not due to tumour uptake of free drug that
had been released from liposomes in the circulation.
Specifically, although vincristine levels in the tumours were
greater for SM/Chol formulations than for DSPC/Chol for-
mulations, the accumulation of liposomes in the tumours was
similar for both systems. The fact that the vincristine-lipid
ratios in the tumours correlated very closely with vincris-
tine-lipid ratios in the plasma for both liposomal formula-
tions indicates that vincristine retention by the lipid carrier is
a key feature affecting both tumour exposure to liposomal
vincristine and the anti-tumour efficacy of liposomal vincris-
tine. It should be noted that, while extravasation to the
peritoneum is dependent on pre-existing vasculature, extra-
vasation to solid tumours occurs after the formation of new
tumour capillaries. Therefore, extravasation of liposomal
drug delivery vehicles to peritoneal and solid tumours may
not be directly comparable. The relative contribution of pass-
ive liposome extravasation via a pore-leakage mechanism vs
liposome extravasation mediated through a cell-dependent
mechanism (transcytosis) is under active investigation.
The pharmacokinetic and therapeutic results presented
here are very similar to those reported recently by Boman et
al. (1994), who found that the presence of the ganglioside
GM, in DSPC/Chol liposomes with an intraliposomal pH of
2.0 significantly increased in vivo vincristine retention within
the liposomes and effected a significant increase in efficacy
against the P388 tumour. The results presented here demon-
strate that a formulation with similar pharmacokinetic and
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therapeutic characteristics can be obtained with a relatively
simple mixture composed of sphingomyelin and cholesterol.
This formulation does not require either extreme intra-
liposomal pH conditions or the addition of lipids that confer
extended circulation longevity. In fact, the pharmacokinetic
and tumour accumulation results suggest that SM/Chol
liposomes possess characteristics that extend the circulation
longevity of liposomes. These characteristics appear to be
related to the reduced interaction of SM/Chol liposomes with
both phagocytic cells (M Webb, unpublished observation)
and serum proteins (Table I), similar to the behaviour of
liposomes that contain GM, (Chonn et al., 1992) or PEG-PE
(Blume and Cevc, 1993). It is interesting that the addition of
PEG2,o-PE to SM/Chol liposomes resulted in the expected
increase in liposome circulation longevity, however PEG2,w-
PE also caused a significant increase in the leakage ofvincris-
tine from the liposomes. The net result ofthese effects was no
enhancement of vincristine circulation longevity (Table II).
Further, the results presented here indicated that vincristine
accumulation in the peritoneal cavity (an extravascular site)
and anti-tumour activity against a peritoneal P388 tumour
were not affected by the addition ofPEG2,"-PE to SM/Chol
liposomes. The data presented here question the phar-
macokinetic and therapeutic benefits obtained through the
use of sterically stabilised lipids for relatively membrane-
permeable agents such as vincristine.
It should be noted that several reports have suggested that
sphingomyelin-containing liposomes are more toxic than PC-
containing liposomes (Weereratne et al., 1983; Allen et al.,
1984; Allen and Smuckler, 1985). However, these studies, in
which mice received high-dose chronic injections (10 i.p.
injections during a 20 day period) of liposomes (Weereratne
et al., 1983), found that small unilamellar vesicles containing
sphingomyelin were not different from either controls or
similar PC-containing liposomes (Allen et al., 1984). In addi-
tion, the observed effects (liver granulomas) also occurred in
mice receiving injections of DSPC/cholesterol liposomes
(Allen and Smuckler, 1985). Our data (Table III) suggest that
vincristine formulated in SM/Chol liposomes was not
significantly more toxic than vincristine in DSPC/Chol lipo-
somes. While weight loss associated with the administration
of liposomal vincristine was somewhat greater than that
incurred for free vincristine (Table III), animals receiving free
drug also had more rapid tumour growth,and weight gain
than did the animals receiving liposomal drug. A more
detailed analysis of the toxicities associated with single and
multiple i.v. administrations has recently shown that lipo-
somal vincristine is less toxic than the free drug in mice and
has very similar toxicity to the free drug in beagle dogs
(Kanter et al., 1994). Overall, these results suggest that the
therapeutic index of SM/Chol liposomal vincristine is
significantly better than either free vincristine or vincristine
encapsulated in DSPC/Chol liposomes.
In summary, we have demonstrated that liposomal for-
mulations of vincristine based on sphingomyelin/cholesterol
have several significant advantages over those based on
DSPC/cholesterol. These liposomal formulations are more
resistant to chemical degradation and drug release in vitro.
Further, they also have improved pharmacokinetic and thera-
peutic characteristics. Specifically, the anti-tumour activity of
vincristine can be optimised from a drug that in free form
has only minimal activity against P388 ascitic tumours and
A431 human solid tumours to a drug that causes cures and
significant increases in lifespan. The ability to achieve these
effects without the use of unusual lipids such as GM1 or
sterically stabilised lipids and/or extreme pH conditions in-
creases the likelihood that this technology will be of use for
applications in a variety of human neoplasms.
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